- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00368602
Beta Blocker for Chronic Wound Healing
Beta Adrenergic Receptor Modulation of Burn Wound Healing
Study Overview
Detailed Description
The purpose of this study is to learn more about how to heal venous leg ulcers faster and to test the safety of a drug and see what effects it has on a venous leg ulcer.
You will:
- be interviewed and examined
- have a physical exam
- have blood and urine tested
- have photographs taken of the wound
- apply medication to the leg ulcer as directed
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Mather, California, United States, 95655
- Va Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Any race btwn 18 and 85 years of age, inclusive;
- Male or female, neither pregnant nor lactating.
- Informed consent;
Have at least 1 lower extremity ulcer in the gaiter area (knee to ankle):
- Surface area of ≥2 sq. cm. to ≤20 sq. cm.; Ulcer with largest surface area meeting inclusion criteria will be selected.
- If 2 ulcers present with the same surface area, ulcer of longest duration selected.
- Study ulcer must be at least 2 cm from any other ulcer on same extremity.
A viable wound bed free of necrotic tissue post-debridement, if debridement is indicated.
5. Have an Ankle Brachial Index (ABI) >0.7; 6. Presence of either dorsalis pedis or posterior tibialis pulses by Doppler on the study extremity; 7. Have a non-healing (open) ulcer for at least 1 month. Subjects who failed conservative therapy are eligible for the study; 8. Comply with a trial (13 to 17 days) of protocol-specified standard care prior to randomization; 9. Two or more of the following: dermatitis, atrophie blanche, varicosities, hyperpigmentation or lipodermatosclerosis;
Exclusion Criteria:
- Decrease in wound surface area of >35% btwn Screening and Visit 1 (Randomization);
- Cellulitis, osteomyelitis, ulcer with exposed bone, tendon or fascia, or purulent exudates in ulcer area;
- Grade IV ulcer;
- Evidence of study ulcer infection;
- Study ulcer of non-venous etiology;
- Acquired or are known to be infected with HIV;
- Uncontrolled diabetes mellitus;
- Immunodeficiency as defined by serum IgG, IgA, and IgM less than one-half the lower limit of normal;
- Severe protein malnutrition as defined by serum albumin <2.5 g/dL;
- Severe anemia defined as a total of hemoglobin of <10 g/dL for males or <8 g/dL for females;
- Chronic renal insufficiency requiring dialysis;
- Serum aspartate aminotransferase (AST, SGOT, GOT) or serum alanine aminotransferase (ALT, SGPT, GPT) levels greater than twice the upper limit of normal;
- New York Heart Association Functional Classification of IV;
- Deep vein thrombosis (DVT) w/in last 6 weeks or clinical evidence of current DVT;
- Arterial revascularization of the study extremity w/in previous 6 months from the date of Screening Visit;
- History, w/in previous 12 months from date of Screen Visit, of alcohol or drug abuse, particularly methadone or heroin;
- Received previous treatment with the following during the 60 days prior to Screening: Immunosuppressive agents, radiation, chemotherapy, growth factors at the site of the study ulcer, split- or full-thickness skin graft at the site of the study ulcer, biologically-active cellular or acellular product(s) at the site of the study ulcer, investigational drug or device
- Received previous treatment with systemic corticosteroids prior to Screening (Chronic corticosteroids w/in 90 days or short course corticosteroids w/in 30 days)
- Been hospitalized for treatment of any venous ulcer w/in the previous 30 days from Screening.
- Asthma or a history of asthma, obstructive pulmonary disease, myasthenia gravis, hyperthyroidism, history of heart block
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1
This group receives topical beta adrenergic antagonists (Timoptic) plus standard of care.
|
Timoptic to be applied to the target wound daily for up to 12 weeks.
Other Names:
|
PLACEBO_COMPARATOR: 2
The group will be given standard of care with placebo medication.
|
Saline solution with no active ingredients to be applied to the target wound daily for up to 12 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary efficacy parameter will be complete ulcer healing, which is defined as 100% epithelialization with no drainage or need for an absorptive dressing.
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
100% re-epithelialization will be clinically determined at each visit by the Investigator.
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Rivkah R Isseroff, MD, University of California, Davis
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 05-06-00351
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Burns
-
MediWound LtdUnknownBurns, Upper Extremity | Burns, Lower ExtremitySlovakia
-
Singapore General HospitalUnknownAcute Thermal BurnsSingapore
-
American Scitech InternationalJohnson & JohnsonUnknownBurns | Electric BurnsUnited States
-
RenovaCare, IncActive, not recruitingBurns | Burns Second Degree | Burns Deep Second DegreeUnited States
-
MediWound LtdCompletedThermal BurnsUnited States, Israel, Belgium, Czechia, Georgia, Germany, Italy, Romania
-
Sun Yat-sen UniversityCompleted
-
MediWound LtdActive, not recruitingThermal BurnsUnited States, United Kingdom, Spain, Georgia, Belgium, Poland, Germany, Hungary, India, Italy, Netherlands, Romania, Slovakia, Ukraine
-
Virginia Commonwealth UniversityNot yet recruiting
-
The Hong Kong Polytechnic UniversityCompleted
-
St. Justine's HospitalRecruiting
Clinical Trials on Timoptic
-
University of NebraskaPfizerCompleted
-
Loyola UniversityWithdrawnBenign Vascular Periocular LesionsUnited States
-
Alcon ResearchCompletedOcular Hypertension | Open-Angle Glaucoma
-
Rady Children's Hospital, San DiegoValeant PharmaceuticalsCompleted
-
VA Office of Research and DevelopmentVA Northern California Health Care SystemActive, not recruitingChronic Diabetic Foot Ulcers | Diabetic Neuropathic Ulcers | Non Healing WoundUnited States
-
University of California, San DiegoBausch & Lomb IncorporatedCompletedOAG - Open-Angle Glaucoma | OHT - Ocular HypertensionUnited States
-
Fraser HealthWithdrawnIschemic Optic Neuropathy | Optic Neuropathy, Ischemic | Anterior Ischemic Optic Neuropathy | Optic Neuropathy, Anterior IschemicCanada
-
Merck Sharp & Dohme LLCCompletedOcular Hypertension | Glaucoma
-
Inotek Pharmaceuticals CorporationCompletedOcular Hypertension (OHT) | Primary Open-Angle Glaucoma (POAG)United States
-
Wills EyeUniversity of Medicine and Dentistry of New JerseyTerminatedSturge Weber Syndrome | Port-wine MarkUnited States